ReviewImmunity, inflammation and disease2025
The M2 Macrophages Importance Role in Psoriasis.
Review in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Macrophages in psoriasis: a bibliometric analysis of research trends, knowledge gaps, and future directions (2015-2024).Frontiers in medicine · 2026Pooled it
- Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis.Clinical reviews in allergy & immunology · 2026Review
- TRIM28 Promotes Keratinocyte Proliferation and Invasion by Activating NLRP3/SGT1 Axis-Mediated Macrophage Pro-Inflammatory Polarization in an In Vitro Macrophage-Keratinocyte Co-Culture Model.Immunity, inflammation and disease · 2026Article
- Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis.Nature communications · 2026Article
- Exploring the impact of IL-2 cytokine family on skin barrier function: pathophysiology and therapeutic strategies.Molecular biology reports · 2026Review
- Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications.Frontiers in immunology · 2026Review
- Renal macrophage TLR7 signaling in lupus nephritis: from pathogenic mechanisms to therapeutic opportunities.Frontiers in immunology · 2026Review
- Potential Targets and Mechanisms of Saikosaponin D in Psoriasis: A Bioinformatic and Experimental Study on Oxidative Stress.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a chronic autoimmune skin condition that is increasingly prevalent globally, causing significant challenges for affected individuals. The disease is influenced by a combination of genetic factors, environmental triggers, immune system dysfunction, and its systemic nature with comorbidities like cardiovascular diseases and depression. Macrophages, essential immune cells, play a critical role in the pathogenesis of psoriasis, displaying various functions and activation states.
objectiveThis study aims to investigate the impact of M2 macrophages on the progression and management of psoriasis, particularly their ability to support tissue healing and reduce inflammation.
resultsM1 macrophages are involved in early inflammation and pro-inflammatory responses when activated by LPS and IFN-γ, while M2 macrophages are activated by IL-4 and IL-13 to promote anti-inflammatory and tissue repair processes. Imbalance in M1 and M2 polarization can worsen autoimmune conditions such as psoriasis, underscoring the need to regulate macrophage phenotypes for effective disease management. Recent research suggests that targeting M2 macrophages could be a promising therapeutic approach for treating psoriasis, especially through advanced biologic treatments such as anti-IL-17 and anti-IL-23 therapies. Enhancing the function of M2 macrophages has been shown to reduce inflammation and improve outcomes in psoriatic conditions, potentially lowering the risk of comorbidities through early intervention and personalized treatment. Biomarkers like CD163(+) M2 macrophages are associated with disease progression, while treatments that enhance M2 macrophage function, such as PSORI-CM02 and Treg-of-B cell therapies, show potential in alleviating psoriasis symptoms.
conclusionUnderstanding the crucial role of M2 macrophages in psoriasis could pave the way for innovative treatment approaches that regulate immune responses and enhance patient care. Further exploration of macrophage biology in psoriasis may provide fresh perspectives on personalized therapeutic options for managing psoriasis and other inflammatory skin conditions, ultimately improving patient care and quality of life for individuals with this chronic skin condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.